EUVIMEDDescoperă EUVIMED
CrossrefCard informativ

Comparative performance of mFI‐5 and mFI‐11 thresholds in predicting outcomes after holmium laser enucleation of the prostate

Hasim Bakbak, Gurpremjit Singh, Ahmad Abdelaziz, Adam Williams, Juanita Velasquez Ospina, Jonathan E. Katz, Robert Marcovich, Alan Jerome Wein, Hemendra N. Shah

BJUI Compass · 2026-07 · 7 (7)

DOI: 10.1002/bco2.70244 ↗
RezumatDate bibliografice

Rezumat

Abstract Objectives This work aimed to evaluate the safety and efficacy of holmium laser enucleation of the prostate across different degrees of frailty using the 11‐item and 5‐item modified frailty indices and to compare perioperative and postoperative outcomes across multiple frailty thresholds. Materials and Methods We retrospectively reviewed patients who underwent HoLEP at our institution between July 2017 and August 2025. Frailty was assessed using mFI‐11 (cutoffs ≥0.18, ≥0.27, ≥0.36) and mFI‐5 (≥0.40). Perioperative variables, functional outcomes, and postoperative complications were compared. Agreement between frailty definitions was assessed using Cohen's kappa. Logistic regression was used to evaluate complication risk. Results Among 857 patients, overall frailty burden was low ranging from 16.2% with mFI‐11 ≥0.36 to 52.6% with mFI‐11 ≥0.18, and 27.5% by mFI‐5 ≥0.40. Functional outcomes improved in all groups, though patients defined as frail by mFI‐11 ≥0.36 demonstrated less improvement in IPSS at 1 year and lower Qmax at select time points. Major complications were uncommon and did not demonstrate a consistent frailty gradient. Transfusion risk was higher only at mFI‐11 ≥0.36. Urinary tract infection showed a dose–response relationship with increasing mFI‐11, with approximately a 20% increase in odds per one‐point increase. Conclusions HoLEP is safe and effective across frailty definitions. Frailty cutoff selection meaningfully influences risk stratification, with mFI‐11 ≥0.36 providing the most clinically informative discrimination.

Cunoștințe potrivite muncii dumneavoastră.

De la începutul gratuit și cercetarea bibliografică personală până la Research Suite complet.

Vezi tarifele →

Sunt incluse toate textele integrale ale editorilor?

Nu. Referințele bibliografice, rezumatele și textele integrale sunt conținuturi diferite. Disponibilitatea unui text integral depinde de sursă, de Open Access și de licențele pe care le aveți deja. Un abonament EUVIMED nu înlocuiește drepturile suplimentare ale editorilor.

Vezi tarifele →